Luye Pharma, owners eye up to US$764m from HK IPO
Drugmaker selling shares after 2012 delisting from SGX
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[SINGAPORE] Luye Pharma Group Ltd, a Chinese drugmaker backed by Singapore's sovereign wealth fund, and existing owners are seeking to raise as much as US$764 million from a Hong Kong initial public offering.
The company and its investors are selling 999.6 million shares at HK$5.38 to HK$5.92 each, according to terms for the deal obtained by Bloomberg News.
The shareholders include GIC Pte as well as Chinese private equity firms CDH Investments Fund Management Co and Citic Private Equity Funds Management Co, the terms show.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
